AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug
AstraZeneca has acquired the global rights to Dizal Pharmaceutical’s Zegfrovy (sunvozertinib), marking the drugmaker’s second venture to China in a…
14 Jul 2026
Novartis and Chai Discovery collaborate on antibody identification
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies. The agreement grants Novartis access to Chai Discovery’s latest AI…
14 Jul 2026
Cellares and Sonoma partner to automate cell therapy manufacturing
Cellares and Sonoma Biotherapeutics have entered a collaboration to automate the manufacturing of the latter’s lead cell therapy programme, SBT-77-7101, using the Cellares Cell Shuttle platform. SBT-77-7101 is described as…
13 Jul 2026
Germany approves healthcare costs overhaul despite significant pharma opposition
Lawmakers in Germany have passed a bill that will cut health insurance costs in a shakeup that has generated strong resistance from global drugmakers. Germany’s Bundestag, the country’s primary legislative…
13 Jul 2026
“Hub-and-spoke” drug manufacturing set to benefit from new FDA rule
The US Food and Drug Administration (FDA) has proposed a new rule that will simplify the registration step for certain drug manufacturers with multiple facilities. The new framework, which is…
13 Jul 2026
Takeda and Indonesia partner on plasma-derived therapies
Takeda and the Indonesian Government have announced a multi-phased collaboration to strengthen the country’s plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs). The Ministry of Health of the…
13 Jul 2026
FDA approves MSD’s Keytruda combinations for MIBC
The US Food and Drug Administration (FDA) has approved two of Merck & Co’s (MSD) Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each combined with Padcev (enfortumab vedotin-ejfv),…